Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

[Osteoimmunologic regulation of aging].

Matsuo K.

Clin Calcium. 2013 Jan;23(1):59-64. doi: CliCa13015964. Review. Japanese.

PMID:
23268303
2.

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE.

J Mol Med (Berl). 2001 Jun;79(5-6):243-53. Review.

PMID:
11485016
3.

[The OPG/RANKL/RANK system and bone resorptive disease].

Liu JZ, Ji ZL, Chen SM.

Sheng Wu Gong Cheng Xue Bao. 2003 Nov;19(6):655-60. Review. Chinese.

PMID:
15971575
4.

[The role of RANK/RANKL and OPG in multiple myeloma].

Zdzisińska B, Kandefer-Szerszeń M.

Postepy Hig Med Dosw (Online). 2006;60:471-82. Review. Polish.

5.
6.

Action of RANKL and OPG for osteoclastogenesis.

Kobayashi Y, Udagawa N, Takahashi N.

Crit Rev Eukaryot Gene Expr. 2009;19(1):61-72. Review.

PMID:
19191757
7.
8.

Inflammation and bone loss in periodontal disease.

Cochran DL.

J Periodontol. 2008 Aug;79(8 Suppl):1569-76. doi: 10.1902/jop.2008.080233. Review.

PMID:
18673012
9.

Effects of obesity on bone metabolism.

Cao JJ.

J Orthop Surg Res. 2011 Jun 15;6:30. doi: 10.1186/1749-799X-6-30. Review.

10.

Osteoprotegerin and inflammation.

Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC.

Eur Cytokine Netw. 2002 Apr-Jun;13(2):144-53. Review.

PMID:
12101070
11.

The RANK/RANKL/OPG triad in cancer-induced bone diseases.

Dougall WC, Chaisson M.

Cancer Metastasis Rev. 2006 Dec;25(4):541-9. Review.

PMID:
17180711
12.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V.

Curr Pharm Des. 2001 May;7(8):613-35. Review.

PMID:
11375772
13.

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Trouvin AP, Goëb V.

Clin Interv Aging. 2010 Nov 19;5:345-54. doi: 10.2147/CIA.S10153. Review.

15.

Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Wagner D, Fahrleitner-Pammer A.

Wien Med Wochenschr. 2010 Sep;160(17-18):452-7. doi: 10.1007/s10354-010-0818-x. Epub 2010 Aug 16. Review.

PMID:
20714810
16.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

17.

[Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent].

Andelković Z, Katić V, Mihajlović D, Zivković V, Petrović A, Lalosević D.

Med Pregl. 2005 Jul-Aug;58(7-8):362-7. Review. Serbian.

PMID:
16296579
18.

Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies.

Anandarajah AP, Schwarz EM.

Adv Exp Med Biol. 2009;649:85-99. Review.

PMID:
19731622
19.

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.

Takahashi N, Udagawa N, Suda T.

Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. Review.

PMID:
10080918
20.

Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.

Tanaka S.

Am J Nephrol. 2007;27(5):466-78. Epub 2007 Jul 25. Review. Erratum in: Am J Nephrol. 2007;27(5):544.

PMID:
17652963
Items per page

Supplemental Content

Write to the Help Desk